This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing’s diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases.
This Funding Opportunity Announcement (FOA) invites applications for studies to understand the effects of type 1 diabetes (T1D) on bone mass and quality and/or fracture risk.
This Funding Opportunity Announcement (FOA) encourages applications from integrative teams and individual investigators for projects to determine the mechanisms underlying the contribution of these risk-associated genes and their variants for Type 1 Diabetes
The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted.
JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce that Eli Lilly Canada Inc. has provided $120,000 in support of two CCTN Post-Doctoral Fellows for one year in the sum of $60,000 each.
JDRF is committed to facilitating the discovery and translation of promising targets or therapeutics to improve and restore glycemic control in people with type 1 Diabetes (T1D).
The NIDDK is pleased to share with you a list of newly issued Funding Opportunity Announcements (FOAs) that are soliciting research applications relevant to type 1 diabetes and its complications:
Helmsley’s Type 1 Diabetes Program has launched a Request for Proposals – the Future Technologies Initiative (FTI). The goal of the FTI is to incubate proof-of-concept, early-stage research and development in the following two tracks:
The goal of this Funding Opportunity Announcement (FOA) is to stimulate bioengineers, physiologists, bio-behavioral researchers, and designers in academic centers and small businesses to develop new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies including open and closed loop hormone replacement systems.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel biomaterials and devices for type 1 diabetes (T1D) treatment.